Ablevia removes disease-causing and other undesired antibodies
Ablevia biotech GmbH
Maria Jacobi Gasse 1, MQM 3.2
supported by BMWFW / aws & FFG
Initial private investments in combination with non-dilutive funding by federal institutions, supports technology setup and facilitates Ablevia's independence in seed phase. Ablevia has received funding from the Austrian Research Promotion Agency (FFG Early Stage program) and was awarded a Seedfinancing program by the Austrian promotional bank aws.
Austrian Research Promotion Agency
Location on Google Maps - here
selective antibody removal therapeutics